BioVie Inc.
BIVI
BioVie Inc. (the Company or we or our ) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. Neurodegenerative Disease Program The Company acquired the biopharmaceutical assets of NeurMedix, Inc. ( NeurMedix ) a privately held clinical-stage pharmaceutical company and a related party in Jun…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$23M
▼ -25.8% YoY
Op. Margin
–
ROIC
-137.72%
▼ -57.6pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$19M
Net Debt
-$7M
Net Cash Position
Cash & Equiv.
$8M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with BIVI
BioVie (BIVI) in two numbers
Questions about BioVie
Does BioVie (BIVI) pay a dividend?
No. BioVie (BIVI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 5 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BIVI's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BIVI
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.